BioWorld

June 4, 2004

View Archived Issues

BioMarin Reports Positive Phase III Aryplase Results

BioMarin Pharmaceutical Inc. on Thursday released favorable data from a Phase III trial of Aryplase, an enzyme-replacement therapy for mucopolysaccharidosis-VI patients. (BioWorld Today) Read More

Maxygen Sells Plant Sciences Unit To DuPont For $64M Cash

Read More

FDA, CV Therapeutics Nail Down Ranexa Trial Protocol

Read More

Panacos, Vitex Merging In $27M Stock Exchange, Plus Milestones

Read More

Other News To Note

Read More